UK NEQAS

Immunology, Immunochemistry & Allergy

ANCA and GBM Antibodies

Accreditation Status: UKAS Schedule of Accreditation

Date Scheme started: 1987

Clinical Applicability: Diagnosis of autoimmune disease

Analytes: Identification of the Neutrophil Cytoplasmic Antibodies, C-ANCA, P-ANCA,

and Glomerular Basement Membrane (GBM). Quantitative assessment is currently restricted to the Proteinase 3 (PR3) and Myeloperoxidase (MPO) $^{\circ}$

antibodies and to GBM antibodies, but will be extended to include

other ANCA specificities as required

Units for Reporting: Qualitative responses for the ANCA specificities; quantitative assessment

of the specific antibodies in U/mL and IU/mL

Samples Distributed: Liquid format. Normal and pathological human serum

Number of Distributions per year: 6

Number of Samples per Distribution: 2

Frequency of Distributions: Every two months as outlined in the Distribution Schedule

Schedule of Analysis: Data entry is via the web for the submission of results. Data analysis

is commenced 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics

Data Analysis: Qualitative responses for ANCA (C-ANCA and P-ANCA), MPO, PR3

and GBM are assessed in relation to the Designated Response

Performance Scoring: MI scoring

Criteria of Performance: Laboratory performance for ANCA is assessed over a running analytical

window of 6 Distributions (12 months). The categories of performance $\,$

are:

 Good
 Zero

 Adequate
 1-2

 Poor
 >2

An OMIS of 3 or more for any one analyte will also be classified as poor

performance.

Persistent Poor Performance: Defined as being in the Poor Performance category for two or more

successive Distributions